Cell therapy manufacturing is one of the most exciting and demanding areas in life sciences. It sits at the intersection of advanced biology, personalised medicine, complex supply chains and highly controlled GMP operations. For QA and QC teams, the challenge is clear: how do we scale cell therapy manufacturing without losing the quality control discipline that protects patients?
This is not a theoretical question. As more cell and gene therapy products move from early clinical development towards later-stage trials and commercial supply, manufacturing models must mature. Manual processes, small batch sizes, open handling steps, variable starting materials and high operator dependency can become increasingly difficult to manage at scale. The FDA’s CMC guidance for human gene therapy IND applications highlights the need for sufficient chemistry, manufacturing and control information to assure product safety, identity, quality, purity and strength, including potency. For QA and QC leaders, those expectations become more challenging as throughput increases.
Scaling is not simply about making more product. It is about making more product consistently, under control and with evidence that the process remains fit for purpose.
Quality Must Be Designed Into Scale-Up
One of the biggest mistakes organisations can make is treating quality as a final checkpoint. In cell therapy, quality cannot be tested into the product at the end. It must be designed into the manufacturing process, the facility, the analytical strategy, the training programme, the supply chain and the data architecture.
Cell therapies are often highly sensitive to process variation. Small changes in raw materials, cell handling, incubation times, cryopreservation, equipment, media, reagents or environmental conditions can have a meaningful impact on product quality. This is why QA involvement must begin early in any scale-up project. The quality team should be involved before decisions are made on automation, process transfer, facility layout, batch record design, analytical methods, supplier strategy and contamination control.
The EMA’s guideline for investigational advanced therapy medicinal products covers quality, non-clinical and clinical requirements for ATMPs in clinical trials, reflecting the importance of a structured quality approach during development. For QA and QC teams, this reinforces a key point: clinical-stage flexibility does not remove the need for sound quality systems, especially when a product is moving towards larger-scale production.
Controlling Variability Starts With the Starting Material
In traditional pharmaceutical manufacturing, raw materials are controlled tightly against specifications. In autologous and some allogeneic cell therapy models, the starting material itself may be biologically variable. Patient-derived or donor-derived cells can differ significantly in quality, viability, cell count and functional characteristics.
This variability cannot be ignored. QC teams need robust incoming material controls, clear acceptance criteria, strong chain of identity and chain of custody systems, and procedures for managing borderline or atypical starting material. QA teams must ensure that decisions are documented, justified and aligned with approved procedures.
For allogeneic therapies, scale-up may involve larger donor-derived cell banks or expanded production models. This can improve standardisation, but it also increases the importance of cell bank characterisation, traceability, testing strategy and contamination control. For autologous therapies, the challenge is different: each patient batch may be unique, but the process must still be controlled and reproducible.
Automation Can Help, But It Is Not a Shortcut
Automation is often seen as the answer to scaling cell therapy manufacturing. It can reduce manual handling, improve consistency, support closed processing, reduce contamination risk and improve data capture. However, automation introduces its own quality responsibilities.
Before implementing automated platforms, QA and QC teams should assess validation requirements, software controls, equipment qualification, data integrity, alarm management, maintenance, calibration and operator training. The goal is not simply to replace people with machines. The goal is to reduce avoidable variability while improving control.
Automation should also be introduced through formal change control. A manual process and an automated process may not be equivalent unless that equivalence is demonstrated. Comparability studies, process validation and analytical data all become essential to show that the scaled process continues to produce a product with the intended quality attributes.
Analytical Methods Must Keep Pace
A common pressure point in cell therapy scale-up is QC testing capacity. As manufacturing expands, laboratories may struggle with sample volumes, method turnaround times, analyst availability and complex release testing requirements.
Potency testing is a particular challenge. Cell therapy products often rely on biological function, and potency assays must be meaningful, reliable and linked to the product’s mechanism of action as far as possible. The FDA’s gene therapy CMC guidance specifically refers to strength, including potency, as part of the information needed to support product quality. As scale increases, QC leaders must ensure that analytical methods are sufficiently robust, qualified or validated as appropriate, and capable of supporting timely batch disposition.
QC scalability should be built into the manufacturing strategy. That means assessing laboratory capacity, sample logistics, assay variability, reference standards, analyst training, data review timelines and potential bottlenecks. A manufacturing process is not truly scalable if the QC release process cannot keep pace.
Contamination Control Becomes More Critical at Scale
As production volume increases, contamination control risk can also increase. More batches, more operators, more materials, more transfers and more facility activity can all create additional exposure points. Closed systems and single-use technologies can help, but they do not remove the need for a strong contamination control strategy.
PIC/S has noted that Annex 2A provides GMP requirements for ATMPs and supports harmonisation with the European Commission’s standalone ATMP GMP guidance. For QA teams, this reinforces the need to view ATMP manufacturing through a specific GMP lens rather than simply applying conventional manufacturing assumptions.
A strong contamination control strategy should consider facility flows, cleanroom classification, environmental monitoring, aseptic practices, gowning, cleaning, disinfection, material transfer, personnel qualification and microbial testing. It should also be reviewed as the process scales. What worked for a small clinical manufacturing suite may not remain sufficient when production increases.
Data Integrity Is Central to Product Confidence
Scaling cell therapy manufacturing generates more data: batch records, environmental monitoring results, equipment data, electronic system records, QC results, deviations, chain of identity records, cryostorage data and shipment information. This data must be complete, accurate, attributable and reviewable.
Electronic batch records, laboratory information systems and manufacturing execution systems can support scale, but they must be properly validated and governed. QA teams should ensure that audit trails, access controls, data review processes, exception reporting and system interfaces are all appropriately managed.
In cell therapy, data integrity is not only a compliance expectation. It is a patient safety requirement. A chain of identity failure, incorrect batch association or incomplete temperature record can have serious consequences.
The QA/QC Talent Challenge
Scaling cell therapy is not only a technical challenge. It is a people challenge. Organisations need QA and QC professionals who understand GMP, biologics, aseptic processing, analytical methods, validation, deviation management, data integrity and advanced therapy-specific risks.
Managers should invest in role-specific training and cross-functional learning. QA teams need to understand the science behind the product, not just the procedure. QC teams need to understand how their methods connect to process performance and batch release. Manufacturing teams need to understand why quality controls matter, especially when commercial pressure increases.
The best QA/QC cultures are not built around policing. They are built around partnership, scientific challenge and disciplined decision-making.
Final Thoughts
Scaling cell therapy manufacturing without losing quality control requires more than extra capacity. It requires a mature quality mindset. Every increase in volume, automation, outsourcing or process complexity must be matched by stronger systems, better data and clearer accountability.
For QA and QC leaders, the priority is to ensure that growth does not dilute control. Scale should make the process more robust, not more fragile. That means investing in comparability, contamination control, analytical readiness, supplier oversight, training, data integrity and risk-based decision-making.
Cell therapies offer enormous promise for patients. Protecting that promise depends on QA and QC teams who can help organisations scale with discipline, evidence and confidence.